PGNY vs VNDA: fair value comparison
Progyny, Inc. and Vanda Pharmaceuticals Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PGNY currently sits closer to the top of our discount ranking. PGNY carries the stronger quality grade.
| PGNY | VNDA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $31.53 | $5.23 |
| 12-month range | $16.86–$31.53 | $4.47–$8.25 |
| Sector rank | #31 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Strong | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: PGNY fair value analysis · VNDA fair value analysis